Stemnovate Next-Gen Platforms
Welcome to Stemnovate—where scientific innovation meets real-world impact. Our unified platform integrates multiomics data, advanced cell technology, and mechanistic functional studies to streamline the path from discovery to the clinic.
Integrated Multiomics Data
Our integrated multiomics platform unites genomics, transcriptomics, proteomics, and metabolomics for a holistic view of disease mechanisms. This enables precision medicine breakthroughs, from rare disorders to complex neurodegenerative conditions.
By connecting diverse molecular insights, we accelerate discovery and development of highly targeted therapies.
Cell Reprogramming & Differentiation
Stemnovate Biobank is dedicated to advancing gender, ethnic, and age diversity in biomedical research by sourcing and preserving a wide range of donor samples. Through cellular reprogramming and directed differentiation, we generate diverse cell types.
This mission ensures equitable access to high-quality cellular models, empowering inclusive and impactful scientific discovery.
Mechanistic Insights
The Stemnovate platform delivers deep mechanistic insights by integrating multiomics and functional data across human and animal models. Our advanced analytics unify diverse datasets, driving comprehensive understanding from molecular pathways to clinical outcomes.
This “One Medicine” approach accelerates translational research and bridges breakthroughs between human and veterinary health.
Faster Clinical Translation
The Stemnovate platform accelerates clinical translation for mitochondrial rare diseases in children, early-onset Parkinson’s, and liver disorders with advanced cellular models. By reducing reliance on animal testing, we champion ethical research while developing species-specific models that enhance both human and animal health.
As the world’s only “One Medicine” platform, we drive breakthroughs across multiple species for truly transformative impact.
Partnerships
Stemnovate partners with top-tier pharmaceutical leaders in both human and animal health, advancing projects in rare diseases and collaborating with the on cutting-edge microengineering. Our academic alliances span the University of Cambridge, Babraham Institute, and University of Edinburgh supporting PhD studentships.
We promote STEM through school work experience and our Ambassador Programme, inspiring future innovators while building a dynamic ecosystem that accelerates research and real-world impact.
Live Campaign for Rare Diseases
Stemnovate’s rare disease programs for children operate under stringent ethical compliance, enabling safe participation of individuals under 18 worldwide. Our inclusive process empowers families to join cutting-edge research and advance treatments tailored to their unique needs.
Live campaigns support ongoing involvement in R&D for mitochondrial disorders, heart, brain, and liver conditions, as well as rare diseases like DMD.
HOW IT WORKS
In vitro Absorption, distribution, metabolism and excretion studies can be conducted on tissues showing multicellular interactions in microphysiological systems.
The multiparametric data obtained from cell studies, assays, protein and gene expression and imaging is used for data analysis and predictive modelling of drug response.
The quantitative data is obtained through biosensors for microenvironment changes and physiological parameter analysis.
Cytochrome P450 studies are complimented with metabolism assays, expression profiling and transcriptomic analysis. A comprehensive data to understand the mechanistic of action or toxicity.
In-depth studies for cell proliferation, apoptosis, receptors & transporters.
Microfluidic device development involves CAD design, 3D printing, prototyping following by application optimisation and manufacturing.
Pharmacogenetics allows the study of the genetic variation due to ethnicity and gender that affects their response or adverse reaction to
medicines or xenobiotics.
Stemnovate has diverse bank of IPS lines that represent the human variability for pharmacogenetics studies.
Our multispecies cellular models allow in vitro studies for mechanism of action, transporters and signalling pathways. This reduced animal testing while the models benefit veterinary drug development and disease modelling.
Cytochromes P450 (CYPs) are the main enzymes involved in drug metabolism. These show huge expression variability among humans. We study CYP inhibition, induction, expression and polymorphism.
Tissue consists of specialised cells functioning while uniquely organised. We simulate this organisation for microphysiological studies. Eg, Liver tissue consists of hepatocytes, stellate and Kupffer cells.
